Navigation Links
Neurocrine Announces 12-Week Safety Results From Initial Phase IIB Study Of VMAT2 Inhibitor NBI-98854
Date:1/9/2014

SAN DIEGO, Jan. 9, 2014 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that NBI-98854, a small molecule VMAT2 inhibitor, in development for tardive dyskinesia, showed an excellent safety profile and a clinically meaningful reduction in tardive dyskinesia symptoms in up to twelve weeks of continuous dosing. This is the second study reporting out this week that demonstrates the potential of NBI-98854 as a safe and highly effective therapy for tardive dyskinesia sufferers. Both of these studies will serve as the foundation for an End of Phase II meeting later this year.

The Kinect study was a randomized, parallel, double-blind, placebo-controlled, Phase IIb clinical trial utilizing the capsule formulation of NBI-98854 in moderate to severe tardive dyskinesia patients with underlying schizophrenia or schizoaffective disorder.  The study assessed NBI-98854 over a six-week placebo-controlled dosing period.  The top-line results from the placebo-controlled portion were previously reported by the Company in September 2013.  Subsequent to the placebo-controlled dosing period, all subjects were eligible to enter a six-week open-label safety extension of 50 mg of NBI-98854 administered once daily, followed by a four-week washout period.

NBI-98854 was generally safe and well tolerated in the Kinect study.  During the twelve-week treatment period the frequency of treatment-emergent adverse events was 40% for NBI-98854, similar to previous clinical trials.  There were no drug related serious adverse events.  The most common treatment-emergent adverse event during the entire twelve-week period was urinary tract infection in six subjects (5.9%) on NBI-98854, which were assessed as not related to study drug by the investigators.  All other adverse events occurred at less than a 3% f
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
2. Neurocrine Biosciences Reports First Quarter 2012 Results
3. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
4. Neurocrine Biosciences Announces Conference Call And Webcast To Present Second Quarter 2012 Financial Results
5. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
6. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
7. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
8. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
9. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
10. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
11. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... 2014  Actavis plc (NYSE: ACT ), a ... Saunders , CEO and President of Actavis, will provide an ... Stanley Global Healthcare Conference 2014 in New York, ... The presentation will take place on Tuesday, September ... Hyatt New York, 109 East 42 nd Street, ...
(Date:8/26/2014)... Research and Markets  has announced the ... 2014-2018" report to their offering. Intranasal ... the administration of drugs for the treatment of local ... allergic and non-allergic rhinitis and sinusitis. The nose is ... vaccination and systematic drug delivery. Continuous ...
(Date:8/26/2014)... comes to diabetes supplies, innovations are often accused of ... answer a real medical need. Fitting ... shows how long it,s been since your last injection. ... insulin doses. Very easy to use, Timesulin starts automatically ... after an injection. There is no settings or complicated ...
Breaking Medicine Technology:Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 3Montméd obtains reimbursement of Timesulin, the smart insulin pen timer cap, by major insurance companies in Canada 2
(Date:8/27/2014)... 27, 2014 ALS Insights is a ... and comfort. It features a series of compelling interviews ... They share their insights, in searing honesty, about issues ... impact on children, what happened in the final days ... Challenge has created a dramatic increase in public awareness ...
(Date:8/27/2014)... Lake City, Utah (PRWEB) August 27, 2014 ... in advancing the business of healthcare, is pleased ... , a ground-breaking online recruitment resource specifically designed ... hiring is undergoing significant changes. To help address ... aging workforce, and tighter budgets—AAPC launched CareerHealth.com ...
(Date:8/27/2014)... CT (PRWEB) August 27, 2014 ... cyclists of all abilities to go the distance this ... Alex’s Million Mile – Run. Walk. Ride. initiative, hosted ... and increase awareness of childhood cancer. September represents ... year’s Alex’s Million Mile, Inspira Marketing Group has teamed ...
(Date:8/27/2014)... August 27, 2014 IntelliSoft Group, LLC, ... management software, will unveil IntelliCred, IntelliApp and ... of Medical Staff Services (NHAMSS) Annual Conference on September ... in Bedford, NH. , Notable improvements available in ... , Contract Linking: A new Contract Connection ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 A recently ... discusses the importance of time in correcting coagulopathy to ... on a variety of anticoagulants and examines medical conditions ... to the research, although anticoagulants have been approved by ... systemic embolism, they are also known to affect the ...
Breaking Medicine News(10 mins):Health News:ALS Insights Launched as Web Resource of Interviews and Information 2Health News:AAPC Responds to Healthcare Workforce Challenges with CareerHealth.com 2Health News:AAPC Responds to Healthcare Workforce Challenges with CareerHealth.com 3Health News:Alex’s Lemonade Stand Foundation Kicks Off Alex’s Million Mile – Run. Walk. Ride. with Labor Day 5k Run in New York City’s Hudson River Park 2Health News:Alex’s Lemonade Stand Foundation Kicks Off Alex’s Million Mile – Run. Walk. Ride. with Labor Day 5k Run in New York City’s Hudson River Park 3Health News:IntelliSoft Group to Unveil Version 14.2 of IntelliCred, IntelliApp and IntelliContract at the New Hampshire Association of Medical Staff Services Annual Conference 2Health News:Flood Law Group Comments on Recent AAICH Study 2
... treatment for recurrent Clostridium difficile infection (CDI), ... the official journal of the American Gastroenterological Association. Additionally, ... to be greater than in some previously reported series, ... rather safe procedure. CDI is a common cause of ...
... 14, 2012Research!America will honor some of our nation,s foremost ... Advocacy Awards tonight at the Andrew W. Mellon Auditorium ... leaders from government, industry, academia and health advocacy organizations ... have made an impact in advancing the nation,s commitment ...
... (HealthDay News) -- High school and college students around the country ... on vacation can ruin the fun. The American College of ... prevent injuries and stay safe while traveling with their friends or ... should go to the nearest ER so we can treat them," ...
... (HealthDay News) -- The drug misoprostol reduced major complications ... a new study. Doctors often use misoprostol for ... now, however, there were no studies large enough to ... complications, either immediate or delayed, according to background information ...
... , WEDNESDAY, March 7 (HealthDay News) -- Researchers report that ... system in patients who received kidney transplants, a process that ... organ instead of trying to reject it. There are ... number of patients. Also, the required procedure is expensive and ...
... Treatment with the common diabetes drug metformin appears ... infected with HIV. In a presentation today ... Infections, Massachusetts General Hospital (MGH) researchers reported that ... essentially no progression of coronary artery calcification during ...
Cached Medicine News:Health News:A new treatment option for Clostridium difficile: Fecal transplantation 2Health News:Research!America honors leading health research advocates 2Health News:Spring Break Safety Tips to Keep Vacation Fun 2Health News:Drug Reduces Complications in Surgical Abortions: Study 2Health News:Transplant Procedure Creates 'Hybrid' Immune System to Combat Rejection 2Health News:Transplant Procedure Creates 'Hybrid' Immune System to Combat Rejection 3Health News:Diabetes drug halts atherosclerosis progression in HIV-infected patients 2Health News:Diabetes drug halts atherosclerosis progression in HIV-infected patients 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: